Published in Eur J Clin Pharmacol on January 01, 1982
Cimetidine, but not oxmetidine, penetrates into the cerebrospinal fluid after a single intravenous dose. Br J Clin Pharmacol (1982) 1.02
Maintenance treatment of recurrent peptic ulcer by cimetidine. Lancet (1978) 3.69
Cimetidine in the treatment of active duodenal and prepyloric ulcers. Lancet (1976) 3.61
Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut (1996) 2.40
Use of air enema radiography to assess depth of ulceration during acute attacks of ulcerative colitis. Lancet (1996) 2.03
Damage to porcine islets of Langerhans after exposure to human blood in vitro, or after intraportal transplantation to cynomologus monkeys: protective effects of sCR1 and heparin. Transplantation (2000) 1.83
Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Ups J Med Sci (2000) 1.74
The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand J Gastroenterol (1999) 1.69
Gas chromatographic assessment of the reproducibility of phenazone plasma half-life in young healthy volunteers. Eur J Clin Pharmacol (1974) 1.68
Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes (1999) 1.65
The absorption of cimetidine before and during maintenance treatment with cimetidine and the influence of a meal on the absorption of cimetidine--studies in patients with peptic ulcer disease. Br J Clin Pharmacol (1979) 1.59
A common methylenetetrahydrofolate reductase gene mutation and longevity. Atherosclerosis (1998) 1.50
Stereoselective pharmacokinetics of S-salbutamol after administration of the racemate in healthy volunteers. Eur Respir J (1999) 1.45
Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease. Scand J Gastroenterol (1984) 1.44
Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis (2002) 1.39
Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease. Gut (1993) 1.39
Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells. Anticancer Drugs (2001) 1.33
Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant (1997) 1.33
Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. Scand J Urol Nephrol (1998) 1.30
Pain is temporally related to eating but not to defaecation in the irritable bowel syndrome (IBS). Patients' description of diarrhea, constipation and symptom variation during a prospective 6-week study. Eur J Gastroenterol Hepatol (1998) 1.29
A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomater Med Devices Artif Organs (1983) 1.25
ATP is required for in vitro assembly of MHC class I antigens but not for transfer of peptides across the ER membrane. Cell (1991) 1.23
Biosynthesis of heparin. 3. Formation of iduronic acid residues. J Biol Chem (1974) 1.20
Spontaneous systemic lupus erythematosus and acelylator phenotype. Acta Med Scand (1977) 1.19
Lipoprotein abnormalities without hyperlipidaemia in moderate renal insufficiency. Nephrol Dial Transplant (1994) 1.17
Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer (2003) 1.16
A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther (2000) 1.13
Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood (1998) 1.11
Antacid/anticholinergic, cimetidine, and placebo in treatment of active peptic ulcers. Scand J Gastroenterol (1981) 1.08
Histologic changes in the gastroduodenal mucosa after long-term medical treatment with cimetidine or parietal cell vagotomy in patients with juxtapyloric ulcer disease. Scand J Gastroenterol (1988) 1.07
The co-polymeric structure of pig skin dermatan sulphate. Distribution of L-iduronic acid sulphate residues in co-polymeric chains. Biochem J (1975) 1.07
Active oxygen induced DNA strand breakage and poly ADP-ribosylation in promotable and non-promotable JB6 mouse epidermal cells. Carcinogenesis (1988) 1.07
Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int (1998) 1.07
Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br J Cancer (2005) 1.05
Reciprocal inhibition during the tonic stretch reflex in the decerebrate cat. J Physiol (1978) 1.04
Division of the irritable bowel syndrome into subgroups on the basis of daily recorded symptoms in two outpatients samples. Scand J Gastroenterol (1999) 1.04
The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function. Br J Clin Pharmacol (1982) 1.04
Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. Br J Cancer (1996) 1.03
Cerebrospinal fluid concentrations of propofol during anaesthesia in humans. Br J Anaesth (1998) 1.02
Pharmacokinetic models for the saturable distribution of paclitaxel. Drug Metab Dispos (1999) 1.02
Cimetidine, but not oxmetidine, penetrates into the cerebrospinal fluid after a single intravenous dose. Br J Clin Pharmacol (1982) 1.02
Evaluation of the sulphapyridine acetylator phenotyping test in healthy subjects and in patients with cardiac and renal diseases. Acta Med Scand (1977) 1.01
Gas chromatographic determination of ethosuximide and phensuximide in plasma and urine of man. J Pharm Pharmacol (1973) 1.01
The effects of cimetidine (Tagamet) on renal function in patients with renal failure. Acta Med Scand (1980) 1.01
The effect of cimetidine, a new histamine H2-receptor antagonist, on renal function. Acta Med Scand (1979) 1.01
A new in vitro model to study interaction between whole blood and biomaterials. Studies of platelet and coagulation activation and the effect of aspirin. Biomaterials (1999) 0.99
Short- and long-term treatment with cimetidine in peptic ulcer disease and the pharmacokinetics of cimetidine. Scand J Gastroenterol Suppl (1979) 0.98
Cimetidine or parietal-cell vagotomy in patients with juxtapyloric ulcers. Lancet (1984) 0.98
Differential anti-inflammatory and anti-oxidative effects of dexamethasone and N-acetylcysteine in endotoxin-induced lung inflammation. Clin Exp Immunol (2000) 0.98
CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Cancer Res (1999) 0.97
Treatment with cimetidine, antacid, or placebo in patients with dyspepsia of unknown origin. Scand J Gastroenterol (1988) 0.97
Relative therapeutic index between inhaled formoterol and salbutamol in asthma patients. Respir Med (2002) 0.95
End-stage chronic renal failure due to total uterine prolapse. Acta Obstet Gynecol Scand (1982) 0.95
Prizidilol, an antihypertensive with precapillary vasodilator and beta-adrenoceptor blocking actions, in primary hypertension. Clin Pharmacol Ther (1981) 0.94
Contact between a polymer and whole blood: sequence of events leading to thrombin generation. J Lab Clin Med (2001) 0.94
Food-stimulated acid secretion measured by intragastric titration with bicarbonate in patients with duodenal and gastric ulcer disease and in controls. Scand J Gastroenterol (1978) 0.94
The functional heterogeneity of eosinophil cationic protein is determined by a gene polymorphism and post-translational modifications. Clin Exp Allergy (2007) 0.94
Tubing loops as a model for cardiopulmonary bypass circuits: both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model. J Clin Immunol (1996) 0.94
A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther (1998) 0.93
Overview of the clinical efficacy of investigational anticancer drugs. J Intern Med (2003) 0.93
Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome? Leukemia (2000) 0.93
SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma. Anticancer Drugs (1992) 0.93
Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol (1998) 0.92
Enantioselectivity in Candida antarctica lipase B: a molecular dynamics study. Protein Sci (2001) 0.92
Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin Oncol (1995) 0.92
The combination of pivampicillin and pivmecillinam versus pivampicillin alone in the treatment of acute pyelonephritis. Scand J Infect Dis (1986) 0.92
Intestinal microsporidiosis in a HIV-seronegative patient. Scand J Infect Dis (1998) 0.91
Pharmacokinetics of captopril and its effects on blood pressure during acute and chronic administration and in relation to food intake. J Cardiovasc Pharmacol (1985) 0.91
Two-year follow-up after one year's treatment with cimetidine or placebo. Lancet (1980) 0.90
Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol Oncol (1994) 0.90
Cytotoxic activity of calcein acetoxymethyl ester (Calcein/AM) on primary cultures of human haematological and solid tumours. Eur J Cancer (1996) 0.89
Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic. Eur J Cancer (1999) 0.89
Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur J Clin Pharmacol (1998) 0.89
Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators. Int J Cancer (1991) 0.89
Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170-kDa P-glycoprotein. Int J Cancer (1994) 0.89
Binding of a model regulator of complement activation (RCA) to a biomaterial surface: surface-bound factor H inhibits complement activation. Biomaterials (2001) 0.89
High gastric bile acid concentration in prepyloric ulcer patients. Scand J Gastroenterol (1985) 0.89
Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology. Biochem Pharmacol (2001) 0.89
Surgery for Crohn colitis over a twenty-eight-year period: fewer stomas and the replacement of total colectomy by segmental resection. Scand J Gastroenterol (2002) 0.89
1,25(OH)2D3 inhibits hormone secretion and proliferation but not functional dedifferentiation of cultured bovine parathyroid cells. Calcif Tissue Int (1988) 0.88
Titanium is a highly thrombogenic biomaterial: possible implications for osteogenesis. Thromb Haemost (1999) 0.88
Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein. Anticancer Drugs (1994) 0.87
Oxidants stress induces the proto-oncogenes, C-fos and C-myc in mouse epidermal cells. Bull Cancer (1990) 0.87
Effect of cimetidine and oxmetidine on 24-h gastric acid and pepsin in patients. Scand J Gastroenterol (1983) 0.87
Improved biocompatibility of intraocular lenses by heparin surface modification: a 12-month implantation study in monkeys. J Cataract Refract Surg (1990) 0.87
An estimation of the annual incidence of poisoning using automated telephone polling. J Toxicol Clin Toxicol (1990) 0.87
Coupled-column chromatography on a Chiral-AGP phase for determination of amlodipine enantiomers in human plasma: an HPLC assay with electrochemical detection. J Pharm Biomed Anal (1996) 0.87
Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol (1996) 0.87